SCHEMBL17276100

SCHEMBL17276100

COC(=O)c1ccc2c(c1)/C(=N\O)CCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.44
KDM4E B2RXH2 2/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
HPGD P15428 1/20 0.44
NPC1 O15118 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PLA2G1B P04054 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
XDH P47989 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
ALDH1A1 P00352 3/20 0.41
ATM Q13315 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4456893 1.00 MAPT (0.44) MAPTKDM4EL3MBTL1HPGDNPC1
SCHEMBL17276101 1.00 MAPT (0.44) MAPTKDM4EL3MBTL1HPGDNPC1
SCHEMBL13131602 0.97 L3MBTL1 (0.47) MAPTKDM4EL3MBTL1HPGDNPC1
SCHEMBL803507 0.91 MAPK14 (0.44) MAPTKDM4EL3MBTL1HPGDNPC1
SCHEMBL13131193 0.91 MAPK14 (0.44) MAPTKDM4EL3MBTL1HPGDNPC1
SCHEMBL1270477 0.89 L3MBTL1 (0.44) MAPTKDM4EL3MBTL1HPGDNPC1
SCHEMBL1270478 0.89 L3MBTL1 (0.44) MAPTKDM4EL3MBTL1HPGDNPC1
SCHEMBL10247479 0.89 L3MBTL1 (0.44) MAPTKDM4EL3MBTL1HPGDNPC1
SCHEMBL2854908 0.82 ALDH1A1 (0.59) MAPTKDM4EL3MBTL1HPGDNPC1
SCHEMBL803937 0.82 ALDH1A1 (0.59) MAPTKDM4EL3MBTL1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3145915-B1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC (US) 2025-03-19 EP disclosed
US-10000454-B2 Antidiabetic tricyclic compounds MERCK SHARP & DOHME (US) 2018-06-19 US disclosed
US-20170081287-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC 2017-03-23 US disclosed
WO-2015176267-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2015-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000454-B2 Antidiabetic tricyclic compounds GPR119, GPR65, GPR52 MAPT 4137/4885KDM4E 3958/4885L3MBTL1 4256/4885
US-20170081287-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS GPR119, GPR65, GPR52 MAPT 4137/4885KDM4E 3958/4885L3MBTL1 4256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.